The Company

We are Biosidus, an Argentina-based company with an impressive track-record in the development, manufacture and supply of top quality biosimilars commercially available across four continents through a vast network of licensees.

We focus our current R&D activities on accelerating market entry of our robust pipeline of biosimilars and on other innovative technologies such as Gene Therapy applied to the management of central and peripheral vascular disease and Transgenic Animals, productive technological platform to obtain human proteins and functional food.


New Technologies/ view all

  • Transgenic animals to produce therapeutic proteins

    Biosidus has concluded is working on novel technologies for high-yield and cost-effective production of recombinant proteins for pharmaceutical applications.

  • Gene Therapy

    Angiogenesis and muscle regeneration using the vascular endothelial growth factor.
    Vascular endothelial growth factor (VEGF) is a protein that stimulates the growth of blood vessels.

  • Biodiversity

    White Genome Project
    Yet another groundbreaking initiative for Biosidus is the White Genome Project, which aims to isolate, identify and characterize Antarctic bacterial strains for further sequencing of the complete genome.